Brokerages expect that Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) will announce earnings of ($0.68) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Tonix Pharmaceuticals Holding Corp.’s earnings, with the highest EPS estimate coming in at ($0.64) and the lowest estimate coming in at ($0.71). Tonix Pharmaceuticals Holding Corp. reported earnings of ($2.60) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 73.8%. The business is expected to report its next quarterly earnings results on Thursday, November 9th.

On average, analysts expect that Tonix Pharmaceuticals Holding Corp. will report full year earnings of ($2.96) per share for the current year, with EPS estimates ranging from ($3.10) to ($2.81). For the next year, analysts forecast that the business will post earnings of ($2.31) per share, with EPS estimates ranging from ($2.79) to ($1.60). Zacks’ EPS averages are an average based on a survey of research analysts that cover Tonix Pharmaceuticals Holding Corp..

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last announced its quarterly earnings results on Monday, August 14th. The company reported ($0.65) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.13.

A number of equities research analysts recently issued reports on the company. ValuEngine lowered Tonix Pharmaceuticals Holding Corp. from a “sell” rating to a “strong sell” rating in a research report on Monday, October 2nd. Dawson James reissued a “buy” rating and issued a $9.00 target price on shares of Tonix Pharmaceuticals Holding Corp. in a research report on Wednesday, August 23rd. Drexel Hamilton assumed coverage on Tonix Pharmaceuticals Holding Corp. in a research report on Tuesday, August 22nd. They issued a “buy” rating on the stock. Roth Capital raised Tonix Pharmaceuticals Holding Corp. from a “neutral” rating to a “buy” rating and set a $6.00 target price on the stock in a research report on Friday, August 18th. They noted that the move was a valuation call. Finally, Aegis assumed coverage on Tonix Pharmaceuticals Holding Corp. in a research report on Monday, June 26th. They issued a “buy” rating and a $10.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Tonix Pharmaceuticals Holding Corp. presently has an average rating of “Buy” and a consensus target price of $8.33.

In other news, CEO Seth Lederman bought 20,000 shares of the company’s stock in a transaction that occurred on Thursday, August 17th. The shares were acquired at an average price of $3.00 per share, with a total value of $60,000.00. Following the transaction, the chief executive officer now owns 11,166 shares in the company, valued at $33,498. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.00% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of TNXP. Citadel Advisors LLC bought a new position in Tonix Pharmaceuticals Holding Corp. in the first quarter valued at approximately $119,000. Vanguard Group Inc. grew its stake in Tonix Pharmaceuticals Holding Corp. by 28.8% in the second quarter. Vanguard Group Inc. now owns 184,377 shares of the company’s stock valued at $799,000 after purchasing an additional 41,264 shares in the last quarter. Finally, B. Riley Financial Inc. bought a new position in Tonix Pharmaceuticals Holding Corp. in the second quarter valued at approximately $1,637,000. Hedge funds and other institutional investors own 27.97% of the company’s stock.

TRADEMARK VIOLATION WARNING: “-$0.68 Earnings Per Share Expected for Tonix Pharmaceuticals Holding Corp. (TNXP) This Quarter” was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/20/0-68-earnings-per-share-expected-for-tonix-pharmaceuticals-holding-corp-tnxp-this-quarter.html.

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) traded down 0.97% during midday trading on Friday, hitting $4.08. The company had a trading volume of 61,550 shares. The firm’s 50-day moving average is $4.31 and its 200-day moving average is $4.12. The firm’s market capitalization is $30.63 million. Tonix Pharmaceuticals Holding Corp. has a 12-month low of $2.85 and a 12-month high of $9.40.

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

Get a free copy of the Zacks research report on Tonix Pharmaceuticals Holding Corp. (TNXP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with MarketBeat.com's FREE daily email newsletter.